WSG-ADAPT: Trastuzumab Emtansine ± ET vs Trastuzumab + ET in HER2+/HR+ Early Breast Cancer
Slideset - Twelve weeks of trastuzumab emtansine therapy increased the rate of pCR in women with HER2+/HR+ early breast cancer compared with trastuzumab plus endocrine therapy.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Herceptin | Women